Baxter International

Latest Headlines

Latest Headlines

Baxter enters agreement to buy Synovis for $325M

Baxter International ($BAX) has inked an agreement to buy Synovis Life Technologies ($SYNO), a provider of biological and mechanical products for soft tissue repair used in a variety of surgical

Baxter recalls 300K flu vaccines

Baxter International ($BAX) has issued a voluntary recall of 300,000 doses of its popular flu vaccine Preflucel after a higher-than-expected number of side effects were reported in those who got the

Big Pharma VCs may complement traditional venture

Biopharma venture funds are coming into vogue, with Baxter ($BAX) providing a recent example. The company says in GEN that it will create a $200 million fund for investing in early-stage companies

Baxter to establish $200M venture arm

Baxter International is looking to invest in early-stage companies whose offerings complement its existing portfolio of medical products. It will invest up to $200 million in such companies through

Baxter sets up $200M venture arm for early-stage investments

Baxter International is setting up its own corporate venture unit with plans to inject up to $200 million to be invested in early-stage companies with promising new technologies. "Baxter's mission is

Baxter nabs Prism's arrythmia drug in $338M buyout

Just months after gaining an FDA approval for ready-to-use IV formulations of its anti-arrhythmic agent Nexterone, Prism Pharmaceuticals has sealed a $338 million buyout deal with Baxter

Baxter's Preflucel gets EU OK

Baxter International has received the approval of a European repeat mutual recognition procedure by the Austrian Agency for Health and Food Safety for the Preflucel seasonal influenza vaccine. The 13

Study: Baxter's cell-based flu vax effective

Baxter's cell-based flu vaccine Preflucel protected 78.5 percent of recipients from the disease, compared with 73 percent who got the traditional egg-based shot. "At 78.5 percent, we certainly would

FDA orders recall of Baxter pumps

The FDA has ordered Baxter International (NYSE: BAX) to recall and destroy its Colleague infusion pumps from the U.S. market based on what the agency calls the company's "longstanding failure" to

Baxter CEO's compensation dipped in 2009

Baxter International chairman and CEO Robert Parkinson saw his compensation fall to under $14.4 million last year--down from $14.8 million in 2008, according to regulatory filings. Parkinson's salary